Glen Reid
University of Otago
New Zealand
Host: Michael Grusch & Karin Schelch
Programm
Targeting drug-tolerant persister cells to improve therapy outcomes in cancer
A/Prof. Glen Reid is a translational cancer researcher and Head of the Department of Pathology at the University of Otago’s Dunedin School of Medicine. Following his BSc and MSc in Cellular and Molecular Biology at the University of Canterbury, he completed a PhD at the University of Göttingen, Germany, then a 3-year postdoc at the Netherlands Cancer Institute. After working on RNAi therapies at the biotech company Genesis Research & Development in Auckland, he joined ADDRI and The University of Sydney, where his research focused on the role of ncRNAs in cancer biology. This work led to the first clinical trial of a microRNA-based treatment for thoracic cancer. His current research aims to understand the involvement of ncRNA in drug tolerance in lung cancer and melanoma.